Document 2781
 DOCN  M94A2781
 TI    Passive immunotherapy in AIDS: results of a double blind randomised
       study. French Passive Immunotherapy Study Group.
 DT    9412
 AU    Lefrere JJ; Vittecoq D; INTS, hop. St-Antoine, Paris.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(1):226 (abstract no. PB0335). Unique
       Identifier : AIDSLINE ICA10/94369794
 AB    A randomized double-blind controlled trial was conducted to determine
       the long term efficacy of passive immunotherapy (PI) in the treatment of
       symptomatic HIV infection. This prospective trial (IPOO2) included
       symptomatic patients randomized in 2 groups. One group received plasma
       rich in anti-p24 antibody (HIV+P), the other received standard
       seronegative plasma (HIV- P). Each patient in both groups received a 300
       mL infusion every 14 days over a one-year period, in addition to
       zidovudine and other prophylactic treatments. To obtain HIV+P, donors
       were selected among symptomless anti-HIV+ individuals with a CD4 count >
       or = 400 and a high concentration of anti-p24 antibody. The plasmas were
       heated before infusion. Upon the advice of the independent committee,
       the inclusion of new patients ceased in July 1993. At this time, 86
       patients had been included. A significant difference was observed
       between both groups in the delay of appearance of the onset of the first
       AIDS defining event (p < 0.009) and in the cumulative number of events
       (p < 0.0008) over the study period of one-year; 18 deaths occurred
       within the study period, 7 in the treated group and 11 in the controls
       (p = .27). The number of days of hospitalisation was 679 in the treated
       group and 1379 in the control group. Infusions of HIV+P every two weeks
       may favorably modulate the natural history of infection and improve the
       quality of life of AIDS patients.
 DE    Acquired Immunodeficiency Syndrome/MORTALITY/PREVENTION & CONTROL
       AIDS-Related Opportunistic Infections/PREVENTION & CONTROL  Combined
       Modality Therapy  Comparative Study  Double-Blind Method  Human  HIV
       Antibodies/IMMUNOLOGY/*THERAPEUTIC USE  HIV Core Protein p24/*IMMUNOLOGY
       HIV Infections/DRUG THERAPY/*THERAPY  HIV-1/*IMMUNOLOGY  *Immunization,
       Passive  Prospective Studies  Treatment Outcome  Zidovudine/THERAPEUTIC
       USE  CLINICAL TRIAL  MEETING ABSTRACT  RANDOMIZED CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).